Latest ankylosing spondylitis Stories

ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia(®) (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA). The regulatory filings for two new indications for certolizumab pegol are now under review...

Lawrence LeBlond for redOrbit.com - Your Universe Online Researchers continuing the study of the human genome have mapped out four new regions that are associated with a painful and often dangerous condition—Behcet’s disease—found in people with a lineage to ancestors along the Silk Road. The Silk Road was used as an important trade route for nearly 2,000 years, linking the Far East and Europe. But along with the trade of goods and cultures, also came the exchange of disease and...

MOUNTAIN VIEW, Calif., Dec. 5, 2012 /PRNewswire/ -- The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection)...

BRUSSELS, Nov. 13, 2012 /PRNewswire/ -- UCB announced extensive results from the Phase 3 study - RAPID(TM)-axSpA - at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington D.C., U.S. RAPID(TM)-axSpA enrolled patients with active axial spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS) and axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA]). The study showed that...

Use of gut bacteria to treat autoimmune diseases among other research presented at ACR Refuting a belief long held by many physicians, a Mayo Clinic study found that rheumatoid arthritis patients also can get gout. The research is among several studies Mayo Clinic is presenting at the American College of Rheumatology annual meeting in Washington. Researchers also found that gut bacteria has potential to treat autoimmune disorders, rheumatoid arthritis patients are at higher risk for...

ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of HUMIRA(®) (adalimumab). The study evaluated improvements in physical function and health-related quality of life (HRQOL) after 52 weeks in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). These results are being presented at the American College...

Educational Conference on October 20 in Long Beach, California, Helps Young Adults with Arthritis, the Leading Cause of Disability in the United States LOS ANGELES, Oct 12, 2012 /PRNewswire-USNewswire/ -- The Arthritis Foundation is sponsoring the 3(rd) Annual PrimeTime symposium (formerly Arthritis in PrimeTime) on Saturday, October 20 at the Long Beach Renaissance Hotel in Long Beach, California. This premier educational and motivational event fosters active, productive and...

MOUNTAIN VIEW, Calif., Oct. 10, 2012 /PRNewswire/ -- The treatment beyond standard of care for ankylosing spondylitis (AS) pharmacotherapeutics currently consists of a single drug class - tumor necrosis factor (TNF) inhibitors. This unavailability of alternative treatment represents an underserved and potentially significant market that is waiting for exploration. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) United States Market for Ankylosing...

HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response...

Study identifies 5 biomarkers A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, has identified five biomarkers that may predict the progression of structural damage in the spine of patients with Ankylosing Spondylitis (AS) who are already at high risk of disease progression. The German study analysed 64 patients from the German Spondyloarthritis Inception Cohort (GESPIC), due to the presence of radiographic spinal damage...